SL
VRTX icon

Sentinus LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

Sentinus LLC’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$274K Buy
613
+152
+33% +$70.9K 0.02% 455
2025
Q4 		$209K Buy
+461
New +$199K 0.02% 515

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sentinus LLC's VRTX Position: Q1 2026 in Review

Sentinus LLC increased its Vertex Pharmaceuticals (VRTX) stake by 33% in Q1 2026, buying an estimated $70.9K and bringing the position to 613 shares worth $274K. The position accounts for 0.02% of the portfolio, ranked #455.

Sentinus LLC first reported a position in VRTX in Q4 2025 and has held it in 2 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Sentinus LLC held 613 shares of Vertex Pharmaceuticals worth $274K as of Q1 2026.
  • Sentinus LLC bought 152 Vertex Pharmaceuticals shares in Q1 2026, an estimated $70.9K.
  • Vertex Pharmaceuticals made up 0.02% of Sentinus LLC's portfolio in Q1 2026, its #455 holding.
  • Sentinus LLC first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Sentinus LLC's 13F filing for Q1 2026, filed 6 May 2026.